Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab + Chemotherapy in ED-SCLC
NCT01450761Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2011
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Ipilimumab Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival at 38 months. Started Dec 2011; status: completed.
02
Drugs
ipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01450761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01450761.